

# Curriculum



Nome Name:	Luca
Cognome Surname:	FABRIS

ORCID:	0000-0001-8538-6317
Scopus Author ID:	6506027517
WOS Author ID:	n.d.
Sito WEB WEB site:	n.d.

## **POSIZIONE PROFESSIONALE ATTUALE / CURRENT PROFESSIONAL POSITION:**

Posizione attuale Current position:	In servizio
Qualifica Qualification:	Professore Associato (L. 240/10)
Ateneo/Ente/Azienda University/Institution/Company:	Università degli Studi di PADOVA
Nazione Ateneo/Ente/Azienda University/Institution/Company Country:	ITA
Anno inizio Start Year:	2016
Anno fine End Year:	n.d.

## **PRECEDENTI ESPERIENZE LAVORATIVE (ULTIMI 10 ANNI) / PREVIOUS WORK EXPERIENCE ( LAST 10 YEARS):**

Qualifica Qualification:	Professore Associato (L. 240/10)
-----------------------------	----------------------------------

Ateneo/Ente/Azienda University/Institution/Company	Università degli Studi di PADOVA
Posizione Sede Lavorativi (indicare Nazione e Città) Workplace Location (specify Country and City):	Padova, PD, Italia
Anno inizio Start Year:	2016
Anno fine End Year:	0
Descrizione Description:	

### LINGUE / LANGUAGES:

Lingua Language:	Inglese
Scrittura Writing:	C1
Comunicazione Communication:	C1

### AREA/SETTORE SCIENTIFICO-DISCIPLINARE / AREA/SECTOR SCIENTIFIC-DISCIPLINARY

Area scientifico-disciplinare Area scientific-disciplinary:	Scienze mediche
Area scientifico-disciplinare codice Area scientific-disciplinary code:	06
Settore scientifico-disciplinare codice Sector scientific-disciplinary code:	-Gastroenterologia
Settore scientifico-disciplinare codice Sector scientific-disciplinary code:	-MEDS-10/A

Area scientifico-disciplinare Area scientific-disciplinary:	Scienze mediche
Area scientifico-disciplinare codice Area scientific-disciplinary code:	06
Settore scientifico-disciplinare codice Sector scientific-disciplinary code:	-Medicina interna
Settore scientifico-disciplinare codice Sector scientific-disciplinary code:	-MEDS-05/A

### DESCRIZIONE DEI PRINCIPALI RISULTATI SCIENTIFICI CONSEGUITI NEGLI ULTIMI 10 ANNI (CON ANNESSO ELENCO DI MASSIMO 10 PUBBLICAZIONI) / DESCRIPTION OF THE MAIN

## SCIENTIFIC RESULTS ACHIEVED IN THE LAST 10 YEARS (WITH ATTACHED LIST OF MAXIMUM 10 PUBLICATIONS):

<p>Descrizione Description:</p>	<p><i>Prof. Luca Fabris has dedicated his research career to understanding the molecular mechanisms driving liver diseases, particularly cholangiocyte roles in chronic cholangiopathies and cholangiocarcinoma (CCA). Over the past decade, his work has advanced our knowledge of cellular signaling in chronic liver diseases (CLDs), fibropolycystic liver diseases, and cancer, focusing on epithelial-mesenchymal interactions, tumor microenvironment (TME), and fibrogenesis. His early work in Caroli disease and congenital hepatic fibrosis (CD/CHF) revealed how cholangiocytes contribute to fibrosis and the recruitment of fibroinflammatory cells. He demonstrated that <math>\beta</math>-catenin signaling in cholangiocytes leads to the secretion of profibrotic chemokines (CXCL1, CXCL10, CXCL12), which recruit M2 macrophages and drive fibrosis, providing new therapeutic targets (PMID: 26645994). A following study revealed that the mislocalization of Scribble protein, a key regulator of planar cell polarity, was involved in the deregulation of <math>\beta</math>-catenin signaling in fibropolycystic liver diseases (PMID: 35593740). In CCA, his studies have highlighted the complex interplay between malignant cholangiocytes and the TME. He demonstrated that VEGF-A and -C secretion by cancer-associated fibroblasts (CAFs) promotes lymphatic vessel formation in the desmoplastic TME, which can be blocked by anti-angiogenic therapies or navitoclax (PMID: 30553841). Additionally, his work uncovered how CAFs contributed to chemoresistance through the overexpression of MCL-1 and inhibition of caspase-3/7 (PMID: 26296968). He also explored how extracellular matrix proteins like periostin, osteopontin, and tenascin C drove CCA malignancy, particularly in patients with metabolic syndrome (PMID: 36902188). Prof. Fabris research on S100A4 revealed its nuclear expression as an independent marker of poor prognosis in CCA, and he demonstrated that low-dose metronomic Paclitaxel can block its nuclear shuttling by inhibiting SUMOylation (PMID: 27328733). Finally, in his most recent work, he showed the complex interactions between cholangiocytes, pericytes, and endothelial cells in mediating portal vein microthrombosis and respiratory failure in COVID-19, based on a large series of deceased patients from Bergamo and Milan (PMID: 38908437).</i></p>
-------------------------------------	---

## PUBBLICAZIONI / PUBLICATIONS:

<p>Anno della pubblicazione Year of publication:</p>	<p>2024</p>
<p>Citazione Citation:</p>	<p>Cadamuro M, Lasagni A, Radu CM, Calistri A, Pilan M, Valle C, Bonaffini PA, Vitiello A, Toffanin S, Venturin C, Friòn-Herrera Y, Sironi S, Alessio</p>

	MG, Previtali G, Seghezzi M, Gianatti A, Strazzabosco M, Strain AJ, Campello E, Spiezia L, Palù G, Frigo AC, Tosoni A, Nebuloni M, Parolin C, Sonzogni A, Simioni P, Fabris L. Procoagulant phenotype of virus-infected pericytes is associated with portal thrombosis and intrapulmonary vascular dilations in fatal COVID-19. <i>J Hepatol.</i> 2024 Jun 20:S0168-8278(24)02320-1. doi: 10.1016/j.jhep.2024.06.014. PMID: 38908437.
--	---

Anno della pubblicazione Year of publication:	2023
Citazione Citation:	Waddell SH, Yao Y, Olaizola P, Walker A, Jarman EJ, Gournopoulos K, Gradinaru A, Christodoulou E, Gautier P, Boerrigter MM, Cadamuro M, Fabris L, Drenth JP, Kendall TJ, Banales JM, Khamseh A, Mill P, Boulter L. A TGFβ-ECM-integrin signaling axis drives structural reconfiguration of the bile duct to promote polycystic liver disease. <i>Sci Transl Med.</i> 2023 Sep 13;15(713):eabq5930. doi: 10.1126/scitranslmed.abq5930. Epub 2023 Sep 13. PMID: 37703354; PMCID: PMC7615241.

Anno della pubblicazione Year of publication:	2022
Citazione Citation:	Fabris L, Milani C, Fiorotto R, Mariotti V, Kaffe E, Sella B, Sonzogni A, Strazzabosco M, Cadamuro M. Dysregulation of the Scribble/YAP/β-catenin axis sustains the fibroinflammatory response in a PKHD1-/- mouse model of congenital hepatic fibrosis. <i>FASEB J.</i> 2022 Jun;36(6):e22364. doi: 10.1096/fj.202101924R.

Anno della pubblicazione Year of publication:	2022
Citazione Citation:	Olaizola P, Lee-Law PY, Fernandez-Barrena MG, Alvarez L, Cadamuro M, Azkargorta M, O'Rourke CJ, Caballero-Camino FJ, Olaizola I, Macias RIR, Marin JGG, Serrano-Maciá M, Martinez-Chantar ML, Avila MA, Aspichueta P, Calvisi DF, Evert M, Fabris L, Castro RE, Elortza F, Andersen JB, Bujanda L, Rodrigues PM, Perugorria MJ, Banales JM. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models. <i>J Hepatol.</i> 2022 Jul;77(1):177-190. doi: 10.1016/j.jhep.2022.02.007. Epub 2022 Feb 23. PMID: 35217064.

Anno della pubblicazione Year of publication:	2022
Citazione Citation:	Izquierdo-Sanchez L, Lamarca A, La Casta A, Buettner S, Utpatel K, Klumpen HJ, Adeva J, Vogel A, Lleo A, Fabris L, Ponz-Sarvise M, Brustia R, Cardinale V, Braconi C, Vidili G, Jamieson NB, Macias RI, Jonas JP, Marziani M, Hołowko W, Folseraas T, Kupčinskis J, Sparchez Z, Krawczyk M, Krupa Ł, Scripcariu V, Grazi GL, Landa-Magdalena A, Ijzermans JN, Evert K, Erdmann JJ, López-López F, Saborowski A, Scheiter A, Santos-Laso A, Carpino G, Andersen JB, Marin JJ, Alvaro D, Bujanda L, Forner A, Valle JW, Koerkamp BG, Banales JM. Cholangiocarcinoma landscape in

	Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry. J Hepatol. 2022 May;76(5):1109-1121. doi: 10.1016/j.jhep.2021.12.010. Epub 2022 Feb 12. PMID: 35167909.
--	---

Anno della pubblicazione Year of publication:	2019
Citazione Citation:	Fabris L, Fiorotto R, Spirli C, Cadamuro M, Mariotti V, Perugorria MJ, Banales JM, Strazzabosco M. Pathobiology of inherited biliary diseases: a roadmap to understand acquired liver diseases. Nat Rev Gastroenterol Hepatol. 2019 Aug;16(8):497-511. doi: 10.1038/s41575-019-0156-4. PMID: 31165788; PMCID: PMC6661007.

Anno della pubblicazione Year of publication:	2019
Citazione Citation:	Cadamuro M, Brivio S, Mertens J, Vismara M, Moncsek A, Milani C, Fingas C, Cristina Malerba M, Nardo G, Dall'Olmo L, Milani E, Mariotti V, Stecca T, Massani M, Spirli C, Fiorotto R, Indraccolo S, Strazzabosco M, Fabris L. Platelet-derived growth factor-D enables liver myofibroblasts to promote tumor lymphangiogenesis in cholangiocarcinoma. J Hepatol. 2019 Apr;70(4):700-709. doi: 10.1016/j.jhep.2018.12.004. Epub 2018 Dec 14. PMID: 30553841; PMCID: PMC10878126.

Anno della pubblicazione Year of publication:	2016
Citazione Citation:	Cadamuro M, Spagnuolo G, Sambado L, Indraccolo S, Nardo G, Rosato A, Brivio S, Caslini C, Stecca T, Massani M, Bassi N, Novelli E, Spirli C, Fabris L, Strazzabosco M. Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma. Cancer Res. 2016 Aug 15;76(16):4775-84. doi: 10.1158/0008-5472.CAN-16-0188. Epub 2016 Jun 21.

Anno della pubblicazione Year of publication:	2016
Citazione Citation:	Locatelli L, Cadamuro M, Spirli C, Fiorotto R, Lecchi S, Morell CM, Popov Y, Scirpo R, De Matteis M, Amenduni M, Pietrobattista A, Torre G, Schuppan D, Fabris L, Strazzabosco M. Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis. Hepatology. 2016 Mar;63(3):965-82. doi: 10.1002/hep.28382. Epub 2016 Jan 16. PMID: 26645994; PMCID: PMC4764460.

Anno della pubblicazione Year of publication:	2015
Citazione Citation:	Morton SD, Cadamuro M, Brivio S, Vismara M, Stecca T, Massani M, Bassi N, Furlanetto A, Joplin RE, Floreani A, Fabris L, Strazzabosco M. Leukemia inhibitory factor protects

	cholangiocarcinoma cells from drug-induced apoptosis via a PI3K/AKT-dependent Mcl-1 activation. <i>Oncotarget</i> . 2015 Sep 22;6(28):26052-64. doi: 10.18632/oncotarget.4482. PMID: 26296968; PMCID: PMC4694885.
--	---

**DESCRIZIONE DEI PRINCIPALI PROGETTI DI RICERCA E PREMI CONSEGUITI NEGLI ULTIMI 10 ANNI (CON ANNESSO ELENCO DI MASSIMO 10 RISULTATI, INCLUDENDO, A TITOLO DI ESEMPIO, PRINCIPAL INVESTIGATOR O COORDINATORE LOCALE DI PROGETTI DI RICERCA COMPETITIVI NAZIONALI O INTERNAZIONALI, SIGNIFICATIVI PREMI CONSEGUITI PER LA PROPRIA ATTIVITÀ DI RICERCA)/ DESCRIPTION OF THE MAIN RESEARCH PROJECTS AND AWARDS AWARDED IN THE LAST 10 YEARS (WITH ATTACHED LIST OF MAXIMUM 10 ACHIEVEMENTS, INCLUDING, FOR EXAMPLE, PRINCIPAL INVESTIGATOR OR LOCAL COORDINATOR OF NATIONAL OR INTERNATIONAL COMPETITIVE RESEARCH PROJECTS, SIGNIFICANT AWARDS AWARDED FOR YOUR RESEARCH ACTIVITY):**

Descrizione Description:	
-----------------------------	--

Descrizione Description:	RESPONSABILE SCIENTIFICO (PI): Progetto di Ricerca Dipartimentale (PRID/SID) "Mechanisms of fibrogenesis and therapeutic perspectives in congenital hepatic fibrosis: interplay between YAP and $\beta$ -catenin signaling" (cod: SID17_04) (2017-2019) € 29.000.
-----------------------------	---

Descrizione Description:	RESPONSABILE SCIENTIFICO (PI): Progetto di Ricerca "Studio Colangiopatia-ORG-iPSC" condotto presso il reparto di Medicina Generale dell'Azienda Ospedale-Università di Padova, e mirato alla generazione di organoidi epatici in-vitro e di induced pluripotent stem cells (iPSC), derivati da pazienti affetti da colangite sclerosante primitiva e da altre colangiopatie primitive (cod: 4157/AO/17) (2017-2022)
-----------------------------	---

Descrizione Description:	EMBO Fellowship Short Stay for the project: "Role of post-translational modifications in the regulation of the cholangiocarcinoma-stroma cross-talk", awarded with the Basque Government Fellowship, conducted by Dr. P. Olaizola within a collaborative study with the group of Liver Diseases at Biodonostia Health Research Institute (PI: Dr. J. Banales) (HOST 1/9/2019-30/11/2019)
-----------------------------	--

Descrizione Description:	EASL Daniel Alagille Fellowship for the project: "Evaluation of the role of HNF1 $\beta$ deficiency in Cholestatic Liver Disease", conducted by Dr. M.
-----------------------------	--

	Pinon (HOST 1/2/2021-30/1/2022) € 25.000.
Descrizione Description:	Co-PI: Progetto di Ricerca Finalizzata RF-2021-12374493, di tipo Theory-enhancing, Title: "Deciphering the prothrombotic mechanisms in COVID-19: clues from the hepatic involvement" presentato nell'ambito del Bando Ricerca Finalizzata 2021 (2022-2025). € 350.000.
Descrizione Description:	Co-PI: Progetto di Ricerca PNRR-MAD-2022-12376188 sezione Malattie Croniche non Trasmissibili (MCnT) ad alto impatto sui sistemi sanitari e socio-assistenziali, Title: "Elucidating the evil relationship of non-alcoholic fatty liver disease with cardiovascular comorbidities: the complex interplay among genetics, hypercoagulability, inflammation and liver fibrosis" presentato nell'ambito del Bando PNRR 2022 (2022-2025). € 800.000.
Descrizione Description:	Co-PI: Progetto di Rilevante Interesse Nazionale PRIN-2022-AHM4AA, Title: "Disruption of the tumor microenvironment as an innovative therapeutic strategy against intrahepatic cholangiocarcinoma" (2023-2025). € 100.000.
Descrizione Description:	Fellow of the American Association for the Study of Liver Diseases (FAASLD) (2024)
Descrizione Description:	American Physiological Society (APS) Publications 2023 Star Reviewer (2023)
Descrizione Description:	Top Downloaded Paper of Liver International (2018-19)

**DESCRIZIONE DEI PRINCIPALI RISULTATI CONSEGUITI NEGLI ULTIMI 10 ANNI IN TERMINI DI SVILUPPO DI RETI E RELAZIONI SCIENTIFICHE NAZIONALI E INTERNAZIONALI (CON ANNESSO ELENCO DI MASSIMO 5 RISULTATI, INCLUDENDO, A TITOLO DI ESEMPIO, PARTECIPAZIONE O ORGANIZZAZIONE DI CONVEGNI NAZIONALI E INTERNAZIONALI; CONTRIBUTI A CONSORZI DI RICERCA) / DESCRIPTION OF THE MAIN RESULTS ACHIEVED IN THE LAST 10 YEARS IN TERMS OF DEVELOPMENT OF NATIONAL AND INTERNATIONAL SCIENTIFIC NETWORKS AND RELATIONS (WITH ATTACHED LIST OF MAXIMUM 5 RESULTS, INCLUDING, FOR EXAMPLE, PARTICIPATION OR ORGANIZATION OF NATIONAL AND INTERNATIONAL CONFERENCES; CONTRIBUTIONS TO RESEARCH CONSORTIA):**

Descrizione Description:	
-----------------------------	--

Descrizione Description:	Member, H2020 EU COST action CA18122 "EURO-CHOLANGIO-NET", supporting the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Project period: 2019-2023.
-----------------------------	--

Descrizione Description:	Member, H2020 EU COST Action CA22125 "Precision medicine in biliary tract cancer (Precision-BTC-Network)" supporting the European Network for the Study of Cholangiocarcinoma (ENS-CCA) (2023-2027).
-----------------------------	--

Descrizione Description:	INTERNATIONAL PRIMARY SCLEROSING CHOLANGITIS (PSC) STUDY GROUP (2010 - oggi). Nell'ambito di questo gruppo il Prof. Fabris ha svolto le seguenti attività: a) Membro dello Steering Committee (2012-2016) b) Chair del Working Group "Cholangiocarcinoma" (2014-oggi)
-----------------------------	---

Descrizione Description:	9.11.2018 SAN FRANCISCO, USA. 69th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Cholestatic and Biliary Diseases SIG (Special Interest Groups). Advancing Autoimmune Hepatitis Understanding and Care. Session chair (with Prof. C.L. Bowlus).
-----------------------------	---

Descrizione Description:	16-17.09.2022 PADUA, Italy. 10th Congress of the International Society of Gender Medicine (IGM2022). Italian Scientific committee, member.
-----------------------------	--

**DESCRIZIONE DEI PRINCIPALI RISULTATI CONSEGUITI NEGLI ULTIMI 10 ANNI IN TERMINI DI SUPPORTO ALLA COMUNITÀ SCIENTIFICA (CON ANNESSO ELENCO DI MASSIMO 5 RISULTATI, INCLUDENDO, A TITOLO DI ESEMPIO, RESPONSABILITÀ DI DIREZIONE DI COMITATI EDITORIALI; INCARICHI DI VALUTAZIONE DELLA RICERCA PRESSO ISTITUZIONI NAZIONALI O INTERNAZIONALI; RESPONSABILITÀ ISTITUZIONALI ALL'INTERNO DELL'ISTITUZIONE DI APPARTENENZA O DI ALTRE ISTITUZIONI) / DESCRIPTION OF THE MAIN RESULTS ACHIEVED IN THE LAST 10 YEARS IN TERMS OF SUPPORT TO THE SCIENTIFIC COMMUNITY (WITH ATTACHED LIST OF MAXIMUM 5 RESULTS, INCLUDING, FOR EXAMPLE, MANAGEMENT RESPONSIBILITIES OF EDITORIAL COMMITTEES; RESEARCH EVALUATION ROLES AT NATIONAL OR INTERNATIONAL INSTITUTIONS; INSTITUTIONAL RESPONSIBILITIES WITHIN THE INSTITUTION OF AFFILIATION OR OTHER INSTITUTIONS):**

Descrizione	<i>Prof. Fabris is serving as Vice-President of the School of Medicine and Surgery, University of</i>
-------------	---

Description:	<i>Padua (English course). He has been appointed as Vice-President of the National Center for the Study of Health and Gender Medicine, and member of 'Elena Cornaro' University Centre for gender knowledge, cultures and policies. From 2012, he has joined the Yale Liver Center faculty with an adjunct appointment (currently Associate Professor), where he is involved in the program of genetic biliary diseases, cancers and gender-specific differences in liver diseases. As journal service, Prof. Fabris is serving as Associate Editor for Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, and as Editorial Board member of Hepatology, American Journal of Physiology - Gastrointestinal and Liver Physiology, and International Journal of Sex and Gender-Specific Medicine. He has been serving as external expert and/or expert panelist of several European grant agencies (HCERES, NCN, COST, ERC among others).</i>
--------------	---

Descrizione Description:	Associate Professor Adjunct presso il Department of Internal Medicine, Digestive Disease Section - Liver Center, Yale University School of Medicine (New Haven, CT, USA), attualmente co-diretta dal Prof. M. Nathanson e dal M. Strazzabosco (dal 1/7/2018).
-----------------------------	---

Descrizione Description:	Vice-Presidente del CdS in Medicine and Surgery (in lingua inglese), Università di Padova (dall'AA 2024-25). Delegato della Rettrice per l'autorizzazione dei progetti formativi dei tirocinanti del CdS in Medicine and Surgery (lingua inglese), Università di Padova (dall'AA 2024-25).
-----------------------------	--

Descrizione Description:	JOURNAL SERVICE - Membro dell'Editorial Board (EB) della rivista Hepatology, section "Liver Pathobiology" (dal 2023). - Associate Editor (AE) della rivista Biochimica Biophysica Acta (BBA) - Molecular Basis of Disease (dal 2022). - Membro dell'Editorial Board (EB) della rivista American Journal of Physiology - Gastrointestinal and Liver Physiology (dal 2014).
-----------------------------	---

Descrizione Description:	PEER REVIEW GROUPS/GRANT STUDY SECTIONS 2024: External Expert & Rapporteur, COST Association, Open Call OC-2024-1, Brussels (Belgium) 2024: External Expert, Swiss National Science Foundation (SNSF), Bern (Switzerland) 2024: Expert Panel, "NZ5 OPUS 27" National Science Centre, Poland (NCN) 2024: Reviewer, French National Cancer Institute (INCa), call for proposals «Biological and basic sciences for Cancer research 2024» 2024: External Expert, The French National Research Agency - Agence Nationale de la Recherche (ANR), evaluation of projects of the call for proposals CES14 - Physiologie et physiopathologie (AAPG -2024) 2024: External Expert, United States - Israel Binational Science Foundation (BSF) 2023: External Expert, COST Association, Open Call OC-2023-1, Brussels (Belgium) 2023: Remote Referee, ERC-2023-ADG - Step 2 2023: Expert Panel, "NZ5 OPUS 25" National Science Centre,
-----------------------------	--

	<p>Poland (NCN) 2022: External Expert, The French National Research Agency - Agence Nationale de la Recherche (ANR), evaluation of projects of the call for proposals CE14 - Physiologie et physiopathologie (AAPG-2022) 2022: External Expert, Alliance4Rare, Eva Luise and Horst Köhler Foundation 2022 2022: Expert Panel, "NZ5 OPUS 23" National Science Centre, Poland (NCN) 2020-22: Reviewer, Deutsche Forschungsgemeinschaft (DFG), German Association for Medical Research 2020: Expert Panel, "NZ5 OPUS 19" National Science Centre, Poland (NCN) 2020: Reviewer, French National Cancer Institute (INCa), call for proposals «Translational Cancer Research Programme - PRTK 2020» 2020: Reviewer, "Equipes FRM 2020" launched by the French Foundation for Medical Research 2019: Expert Panel, "NZ5 OPUS 17" National Science Centre, Poland (NCN) 2019: Reviewer, French association for the study of the liver (AFEF) 2018-present: REPRIS (albo degli esperti scientifici istituito presso il MIUR) for "Basic Research (dal 15/6/2018) 2017: Reviewer List Member, Israel Science Foundation (ISF) 2017-18: Expert Panel, HCERES Evaluation of the Centre de Recherche Saint-Antoine (CRSA), France 2016-present: Referee of the Italian National Agency for the Evaluation of Research and University System (ANVUR) for VQR assessment 2015-present: Reviewer List Member, The French National Research Agency - Agence Nationale de la Recherche (ANR), National Science Centre, Poland - Narodowe Centrum Nauki (NCN) 2012-2013: Reviewer, Fonds Wetenschappelijk Onderzoek (FWO), Vlaanderen, Belgium 2010-present: Reviewer List Member, Minister of University and Scientific Research, Italy (Ministero dell'Università e della Ricerca Scientifica - MIUR)</p>
--	--

<p>Descrizione Description:</p>	<p>REFeree PER RIVISTE SCIENTIFICHE Journal of Hepatology, Liver International, Digestive and Liver Disease, Gastroenterology, Hepatology, Gut, Expert Opinion on Drug Metabolism and Toxicology, Clinics and Research in Hepatology and Gastroenterology, PlosOne, Gastroenterology Report, Digestive Diseases and Sciences, American Journal of Medical Sciences, Journal of Hematology &amp; Oncology, Cancer Letters, BioMed Research International, Seminars in Liver Disease, Theranostics, Oncotarget, BMC Cancer, BBA-Molecular Basis of Disease, Molecular Carcinogenesis, J Clin Invest, Cancer Res, Cell Death Dis, Cancer Medicine, Cellular Signalling, Journal of Experimental &amp; Clinical Cancer Research, Communications Biology, Clinical Science, Tumor Biology, Redox Biology, Oncogene, Science Translational Medicine, Advanced Science, Archives of Biochemistry and Biophysics, Cells, Cancers, Expert Opinion on Investigational Drugs, Biomaterials, Journal of Pathology, iScience, Med Comm, Advanced Functional Materials, Cancer Communications.</p>
-------------------------------------	--

**DESCRIZIONE DEI PRINCIPALI RISULTATI CONSEGUITI NEGLI ULTIMI 10 ANNI IN TERMINI VALORIZZAZIONE DELLE CONOSCENZE (CON ANNESSO ELENCO DI MASSIMO 3 RISULTATI, RELATIVI ALLA PARTECIPAZIONE DEL CANDIDATO ALLE ATTIVITÀ DI VALORIZZAZIONE DELLE CONOSCENZE) /**

**DESCRIPTION OF THE MAIN RESULTS ACHIEVED IN THE LAST 10 YEARS IN TERMS OF KNOWLEDGE VALORIZATION (WITH ATTACHED LIST OF MAXIMUM 3 RESULTS, RELATING TO THE CANDIDATE'S PARTICIPATION IN KNOWLEDGE VALORIZATION ACTIVITIES):**

Descrizione Description:	
Descrizione Description:	12.4.2024 Padova, Italy. Intervista per Il BO Live "In Salute. Malattie autoimmuni più diffuse nelle donne: cause e nuovi risultati".
Descrizione Description:	5.7.2024 RaiNEWS, intervista dal titolo "Studio, il virus colpisce anche cuore, fegato e reni. Non solo polmoni". Intervento con P. Simioni.
Descrizione Description:	3.7.2024 Roma, Senato della Repubblica, Sala Zuccari, Palazzo Giustiniani, "Medicina di Genere: Attualità e Prospettive", iniziativa promossa del Senato della Repubblica. Seconda Sessione "Differenze di Genere nei Percorsi Clinici e Formativi". "La formazione universitaria in ottica di genere".

**Informazioni aggiornate alla data di candidatura 20-05-2025**

**Luca FABRIS**

*Il presente curriculum costituisce allegato e parte integrante dell'incarico sottoscritto*